Pardes Biosciences is a clinical-stage biopharmaceutical company focused on developing antiviral therapeutics for serious infectious diseases. The company gained significant attention during the COVID-19 pandemic for its work on oral antiviral treatments, positioning itself as a competitor to established players like Pfizer's Paxlovid.
Founded with a mission to address unmet medical needs in antiviral therapy, Pardes has been working on small molecule drugs that can be administered orally, making treatment more accessible. The company operates in the highly competitive but essential infectious disease therapeutics market, where rapid development and regulatory approval are critical for success.
Clinical-stage biopharmaceutical company developing oral antiviral therapeutics for infectious diseases.
Pardes Biosciences operates in the Biotech sector. Clinical-stage biopharmaceutical company developing oral antiviral therapeutics for infectious diseases.
